Cell-cycle synchronization reverses Taxol resistance of human ovarian cancer cell lines

Cancer Cell International

Jie Yin³  Xiangjuan Qin¹  Lifang Sun¹  Ning Mao²  Lingya Pan³  Xueqing Wang¹ 

[1] Department of Obstetrics and Gynecology, Beijing Jishuitan Hospital, The Fourth Teaching Hospital of Beijing Medical College, Beijing, China;Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing, China;Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Peking, China

关键词: Cell-cycle synchronization;    M stage;    Chemoresistance;    Cell cycle;    Thymidine;   

Others  :  793222
DOI  :  10.1186/1475-2867-13-77

 received in 2013-04-16, accepted in 2013-07-24,  发布年份 2013

【 摘 要 】

Background

Taxol is a powerful chemotherapy agent leading to mitotic arrest and cell death; however, its clinical efficacy has been hampered due to the development of drug resistance. Taxol specifically targets the cell cycle. Progress through mitosis (M stage) is an absolute requirement for drug-induced death because cell death is markedly reduced in cells blocked at the G₁-S transition. The measured doubling time for ovarian cancer cells is about 27 h. As such, during treatment with Taxol most of the cells are not in the M stage of the cell cycle. Thus, the effect of cell-cycle synchronization was investigated in regard to reversing Taxol resistance in ovarian cancer cells.

Methods

Giemsa-Wright staining was used for assessing the morphology of the cells. The doubling time of the cells was calculated using formula as follows: Td = In2/slope. The resistant index and cell cycle were measured via MTT assays and flow cytometry. Thymidine was used to induce cell-cycle synchronization, and cell apoptosis rates following exposure to Taxol were measured using a flow cytometer.

Results

The growth doubling time of two Taxol-resistant cell lines were longer than that of Taxol-sensitive cells. Apoptotic rates in Taxol-sensitive and -resistant cell lines after synchronization and exposure to Taxol were all higher compared to unsynchronized controls (p <0.05).

Conclusions

Synchronization of the cell-cycle resulted in an increased effectiveness of Taxol toward ovarian cancer cell lines. We speculated that formation of drug resistance toward Taxol in ovarian cancer could be partly attributed to the longer doubling time of these cells.

【 授权许可】

   
2013 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Slichenmyer WJ, Von Hoff DD: Taxol: a new and effective anti-cancer drug. Anticancer Drugs 1991, 2:519-530.
• [2]Vici P, Conti F, Amodio A, Belli F, Della Giulia M, Mariotti S, Gionfra T, Lopez M: Simultaneous infusion of vinorelbin and taxol as first-line chemotherapy in metastasized breast cancer. Clin Ter 1998, 149:255-259.
• [3]Hájek R, Vorlicek J, Slavik M: Paclitaxel (Taxol): a review of its antitumor activity in clinical studies Minireview. Neoplasma 1996, 43:141-154.
• [4]Young RC: Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer. Semin Oncol 2000, 27:8-10.
• [5]Choi YH, Yoo YH: Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells. Oncol Rep 2012, 28:2163-9.
• [6]Zaniboni A, Ardizzoni A, De Marinis F, Portalone L, Boni C, Meriggi F, Cafferata MA, Ariganello O, Torri V, Neumaier CE, Rosso R: Phase II study of Taxol combi.ned With ifosfamide and carboplatin in the treatment of stage IIIb-IV non-small-cell lung cancer. Am J Clin Oncol 2003, 26:84-8.
• [7]Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST, Kao A: Comparing the relationship of Taxol-based chemotherapy response with P-glycoprotein and lung resistance-related protein expression in non-small cell lung cancer. Lung 2003, 181:267-73.
• [8]Agarwal R, Kaye SB: Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 2003, 3:502-16.
• [9]Lai D, Ho KC, Hao Y, Yang X: Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. Cancer Res 2011, 71:2728-38. Epub 2011 Feb 24
• [10]Umezu T, Shibata K, Kajiyama H, Terauchi M, Ino K, Nawa A, Kikkawa F: Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin. Int J Gynecol Pathol 2008, 27:207-12.
• [11]Bai ZG, Qu X, Han W, Ma XM, Zhao XM, Zhang ZT: Expression of taxol resistance gene 1 correlates with gastric cancer patient clinical outcome and induces taxol resistance. Mol Med Report 2010, 3:1071-8.
• [12]Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT: Plant antitumor agents. The isolation and structure of taxol, a novel antileukemic and antitumor agent from taxus brevifolia. J Am Chem Soc 1971, 93:2325-2327.
• [13]Radulescu S, Ridgway RA, Appleton P, Kroboth K, Patel S, Woodgett J, Taylor S, Nathke IS, Sansom OJ: Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol. Oncogene 2010, 29:6418-27.
• [14]Hornick JE, Bader JR, Tribble EK, Trimble K, Breunig JS, Halpin ES, Vaughan KT, Hinchcliffe EH: Live-cell analysis of mitotic spindle formation in taxol-treated cells. Cell Motil Cytoskeleton 2008, 65:595-613.
• [15]Xing H, Wang S, Weng D, Chen G, Yang X, Zhou J, Xu G, Lu Y, Ma D: Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep 2007, 17:117-22.
• [16]Gazitt Y, Rothenberg ML, Hilsenbeck SG, Fey V, Thomas C, Montegomrey W: Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. Int J Oncol 1998, 13:839-48.
• [17]Panvichian R, Orth K, Day ML, Day KC, Pilat MJ, Pienta KJ: Paclitaxel-associated multimininucleation is permitted by the inhibition of caspase activation: a potential early step in drug resistance. Cancer Res 1998, 15:4667-72.
• [18]Li L, Jiang AC, Dong P, Wang H, Xu W, Xu C: MDR1/P-gp and VEGF synergistically enhance the invasion of Hep-2 cells with multidrug resistance induced by taxol. Ann Surg Oncol 2009, 16:1421-8.
• [19]Kavallaris M, Burkhart CA, Horwitz SB: Antisense of Ligonucleotides to class βII- tubulin sensitive drug-resistant cells to Taxol. Br J Cancer 1999, 80:1020-5.
• [20]Mao QQ, Bai Y, Lin YW, Zheng XY, Qin J, Yang K, Xie LP: Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines. Mol Nutr Food Res 2010, 54:1574-84.
• [21]Wang TH, Wang HS, Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 2000, 1:2619-28.
• [22]Edgar BA, Sprenger F, Duronio RJ, Leopold P, O’Farrell PH: Distinct molecular mechanism regulate cell cycle timing at successive stages of Drosophila embryogenesis. Genes Dev 1994, 15:440-52.
• [23]Mohamed FZ, Hussien YM, Albakry MM, Mohamed RH, Said NM: Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility. Mol Biol Rep 2013, 40:3757-68.
• [24]Rastogi N, Mishra DP: Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div 2012, 26:7-26.
• [25]Long BH, Fairchild CR: Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994, 15(54):4355-61.
• [26]Lee EA, Keutmann MK, Dowling ML: Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 2004, 3:661-9.
• [27]Xue Dong Y, Min L, Ye Y, Ning M, Ling Ya P: Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol Rep 2007, 17:1163-1169.
• [28]Jordan MA, Wilson L: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998, 10:123-30.
• [29]Tsukasaki K, Miller CW, Greenspun E, Eshaghian S, Kawabata H, Fujimoto T, Tomonaga M, Sawyers C, Said JW, Koeffler HP: Mutations in the mitotic check point gene, MAD1L1, in human cancers. Oncogene 2001, 20:3301-5.
• [30]Shichiri M, Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y: Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res 2002, 62:13-7.
• [31]Musio A, Montagna C, Zambroni D, Indino E, Barbieri O, Citti L, Villa A, Ried T, Vezzoni P: Inhibition of BUB1 results in genomic instability and anchorage-independent growth of normal human fibroblasts. Cancer Res 2003, 63:2855-63.
• [32]Hu M, Liu Q, Song P, Zhan X, Luo M, Liu C, Yang D, Cai Y, Zhang F, Jiang F, Zhang Y, Tang M, Zuo G, Zhou L, Luo J, Shi Q, Weng Y: Abnormal expression of the mitotic checkpoint protein BubR1 contributes to the anti-microtubule drug resistance of esophageal squamous cell carcinoma cells. Oncol Rep 2013, 29:185-92.
• [33]Masuda A, Maeno K, Nakagawa T: Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 2003, 163:1109-1116.
• [34]Fu Y, Ye D, Chen H, Lu W, Ye F, Xie X: Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Gynecol Oncol 2007, 105:66-73.
• [35]Gian VG, Johnson TJ, Marsh RW, Schuhmacher C, Lynch JW: A phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas. J Exp Ther Oncol 1996, 1:186-90.
• [36]Patel SR, Papadopoulos NE, Plager C, Linke KA, Moseley SH, Spirindonidis CH, Benjamin R: Phase II study of paclitaxel in patients with previously treated osteosarcoma and its variants. Cancer 1996, 78:741-4.
• [37]Ferlini C, Ojima I, Distefano M, Gallo D, Riva A, Morazzoni P, Bombardelli E, Mancuso S, Scambia G: Second generation taxanes: from the natural framework to the challenge of drug resistance. Curr Med Chem Anticancer Agents 2003, 3:133-8.